Summary
Atray Dixit is a biotech founder and technical leader with nine years of experience translating cutting-edge functional genomics into drug discovery and diagnostics. He co-founded Coral Genomics (acquihired after raising $5.7M) and served as VP of Technology at Gordian, where he led teams building pooled in vivo AAV screens and single-cell processing pipelines. His MIT/Princeton-trained PhD work under Aviv Regev (including Perturb-seq and Shuffle-seq) has been incorporated into patents and the core tech stacks of startups and pharma programs that have collectively raised billions. Beyond genomics, his publications span AI for toxicity prediction, environmental PFAS detection, and 3D tissue printing, showing a rare cross-disciplinary fluency. Currently leading Oncko to discover combination therapies and active in the South Park Commons community, he pairs hands-on lab innovation with product and operational experience (CLIA lab launches, NIH grants, and pharma negotiations). A less obvious strength is his ability to move methods from academic proof-of-concept to scalable, revenue-driving platforms—evidenced by both clinical studies and platform acquihire outcomes.
9 years of coding experience
9 years of employment as a software developer
Doctor of Philosophy (PhD), Doctor of Philosophy (PhD) at Massachusetts Institute of Technology
BSE Mechanical and Aerospace Engineering, BSE Mechanical and Aerospace Engineering at Princeton University
Italian, Gujarati